Spots Global Cancer Trial Database for Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Official Title: Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or High-Risk Myelodysplastic Syndrome: Randomized Phase II Study

Study ID: NCT04482894

Conditions

Leukemia, Acute

AML, Adult

ALL, Adult

Myelodysplastic Syndromes

Interventions

Palliative Care Visits

Study Description

Brief Summary: The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

Detailed Description: Participants in this study will be randomized to either an intervention group or a standard of care group. Participants in the intervention group will participate in regular visits with a palliative (or supportive) care specialist, while participants in the standard of care group will only see palliative care specialists if the clinician requests a referral. All participants will be asked to complete monthly questionnaires regarding their general well-being. Participants have a greater chance of being assigned to the intervention group than to the standard of care group. On average, in every 5 people randomized, 3 will be randomized to the intervention and 2 will be randomized to standard of care.